Rheumatoid Arthritis News

PHILADELPHIA — Discordance with the treatment goals of providers among patients with rheumatoid arthritis was associated with age, gender, age at diagnosis and other factors of care, according to survey data presented at ACR Convergence 2022.

The FDA has accepted an abbreviated biologics license application for a tocilizumab biosimilar candidate, according to a press release from Biogen.

PHILADELPHIA — The initiation of disease-modifying antirheumatic drugs among U.S. veterans with active rheumatoid arthritis requires improvement, regardless of rural or urban setting, according to a presentation at ACR Convergence 2022.

PHILADELPHIA — Significant and distinct shifts in critical “cellular players” were seen among patients with rheumatoid arthritis-associated interstitial lung disease, according to an ongoing study presented at ACR Convergence 2022.

Dementia is more common in patients with rheumatoid arthritis who receive conventional synthetic disease modifying anti-rheumatic drugs vs. biologics or targeted synthetic treatments, according to data.

PHILADELPHIA — Opioid use in rheumatoid arthritis demonstrates a nearly two-fold increased risk for venous thromboembolism vs. NSAIDs, according to data presented at ACR Convergence 2022.

PHILADELPHIA — Prescribing patterns of fellows seeing patients with rheumatoid arthritis in an urban, academic hospital system aligned with the teaching practices of faculty, according to findings presented at ACR Convergence 2022.

PHILADELPHIA — Patients with rheumatic diseases and previous malignancy do not demonstrate a higher cancer risk with TNF inhibitors vs. other biologic and targeted synthetic DMARDs, according to data presented at ACR Convergence 2022.

PHILADELPHIA — A novel program offering rheumatoid arthritis training for primary care providers in the Navajo Nation improved treatment access, according to data presented at ACR Convergence 2022.

PHILADELPHIA — Making sense of real-world data and black-box warnings associated with Janus kinase inhibitors can be challenging for rheumatologists hoping to prescribe these medications, according to a presenter at ACR Convergence 2022.